Imagine going through a painful medical procedure and finding relief without needing strong painkillers. For cancer patients undergoing a procedure called percutaneous transhepatic biliary drainage, a new study explored the use of virtual reality combined with guided breathing techniques to help manage pain. This procedure can be quite uncomfortable, and traditional pain management often relies on opioids, which come with risks of addiction and side effects. In the study, patients who used virtual reality with breathing guidance consumed much less opioid medication the day after the procedure compared to those who used standard virtual reality. While both groups reported similar satisfaction with their experience, the significant reduction in opioid use suggests that this innovative approach could help patients feel better and rely less on medications. However, it's important to note that this was a small study, and more research is needed to confirm these findings and understand how best to implement this method in clinical settings. Still, the potential for virtual reality and breathing techniques to enhance pain management offers hope for a safer and more comfortable experience for patients.
Guided Breathing VR Reduces Opioid Use Post-PTBD in Cancer Patients by 64%Can Virtual Reality and Breathing Techniques Reduce Cancer Pain?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This randomized controlled trial evaluated the analgesic potential of guided breathing virtual reality (VR) in managing pain for cancer patients undergoing percutaneous transhepatic biliary drainage (PTBD). The study involved 45 patients who were randomly assigned to either a VR with guided deep breathing group (VRBG, n=22) or a conventional VR without breath guidance group (VROG, n=23). Both groups experienced two 7-minute VR sessions with calming visuals and narration, while VRBG received additional prompts for slow, rhythmic breathing. The primary endpoint was opioid consumption on the day following PTBD. Results showed that the VRBG group had significantly lower opioid consumption compared to the VROG group, with mean morphine milligram equivalents of 20.25 vs. 56.61 (P=0.044). No significant difference was observed in opioid use on the day of the procedure. Secondary endpoints included patient satisfaction and willingness to reuse VR, which were comparable between groups. Safety was assessed, revealing that mild adverse events were infrequent and self-limiting. These findings suggest that incorporating structured breathing guidance into VR may enhance its analgesic effect and reduce opioid reliance after invasive procedures, offering a promising non-pharmacological adjunct in cancer pain management.